A5011739235- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Viral Infectious Diseases and Gene Expression in Insects
- Liver Disease Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- Ubiquitin and proteasome pathways
- Plant Virus Research Studies
- Immune Cell Function and Interaction
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Polyomavirus and related diseases
- Sarcoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Gut microbiota and health
- Chemokine receptors and signaling
- Hemodynamic Monitoring and Therapy
Hainan Medical University
2025
Universitätsklinikum Würzburg
2019-2024
Beijing Friendship Hospital
2016-2024
Capital Medical University
2016-2024
Peking Union Medical College Hospital
2011-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2011-2024
Beijing Ditan Hospital
2024
University of Würzburg
2019-2023
South China University of Technology
2022-2023
Central South University
2020-2022
Abstract T cell–engaging immunotherapies exert unprecedented single-agent activity in multiple myeloma (MM), thereby putting a yet unexplored selective pressure on the clonal architecture. In this study, we report homozygous BCMA (TNFRSF17) gene deletion after BCMA-targeting cell–redirecting bispecific antibody therapy heavily pretreated MM patient. Loss of protein expression persisted over subsequent relapses, with no response to treatment anti-BCMA drug conjugate. light alternative targets...
Pseudo-progression and flare-up phenomena constitute a novel diagnostic challenge in the follow-up of patients treated with immune-oncology drugs. We present case study on pulmonary after Idecabtagen Vicleucel (Ide-cel), BCMA targeting CAR T-cell therapy, used single-cell RNA-seq (scRNA-seq) to identify Th17.1 driven autoimmune mechanism as biological underpinning this phenomenon. By integrating datasets various lung pathological conditions, we revealed transcriptomic similarities between...
Abstract Introduction Bortezomib (BTZ) is a selective and reversible proteasome inhibitor first line treatment for multiple myeloma (MM). One of the side effects BTZ-induced peripheral neuropathy (BIPN). Until now there no biomarker which can predict this effect its severity. Neurofilament light chain (NfL) neuron specific cytoskeletal protein, higher levels be detected in blood case axon damage. In study, we aimed to evaluate relationship between NfL serum characteristics BIPN. Methods We...
Severe fever with thrombocytopenia syndrome (SFTS) caused by the SFTS virus (SFTSV) is an emerging tick-borne disease a high mortality rate. Haemaphysalis longicornis primary reservoir and vector of SFTSV. Here, we found that targeting subolesin (SUB), anti-tick vaccine candidate, affects infection transmission SFTSV in H. longicornis. RNAi-mediated knockdown SUB repressed salivary glands but not gut longicornis, which may be associated modulation protein processing endoplasmic reticulum...
Zusammenfassung Die medikamentöse Tumortherapie entwickelt sich von der klassischen zytotoxischen Chemotherapie hin zu immer gezielteren Immuntherapien. Im Gegensatz monoklonalen Antikörpern richten bispezifische Antikörper (BsAb) gegen 2 unterschiedliche Antigene und können auf diese Weise entweder Immuneffektorzellen mit Tumorzellen verbinden oder Signalwege in blockieren. Bisher wurden mehrere BsAb zur Behandlung hämatologischer Neoplasien ausgewählter solider Tumoren zugelassen....
Published experience with carfilzomib in patients relapsed/refractory multiple myeloma (RRMM) and extramedullary disease (EMD) is still limited. The current study aimed to assess the efficacy safety of containing therapy regimens EMD. We retrospectively analyzed 45 RRMM treated from June 2013 September 2019. median age at start was 64 (range 40–80) years. Twenty (44%) 25 (56%) had paraosseous manifestation EMD without adjacency bone, respectively. serological overall response rate (ORR) 59%....
Abstract Background Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due demyelination. Patients usually present confusion seizures. Late diagnosis lack adequate therapy options persistently result in permanent impairment brain functions. Due profound T cell depletion, T-cell function potent immunosuppressive factors, allogeneic hematopoietic...
New Findings What is the central question of this study? Diabetic nephropathy (DN) a severe complication diabetes correlated with higher mortality rate in diabetic patients. Renal tubular injury participates pathogenesis DN. We aimed to uncover biological function NEAT1–miR‐150‐5p–DRP1 axis an vitro model DN and elaborate potential mechanisms. main finding its importance? NEAT1 facilitated high glucose‐induced damage HK‐2 cells by reducing mitophagy via miR‐150‐5p–DRP1 axis, which sheds...
Endogenous hypercortisolism predisposes to impaired immune function and infections. To date, however, it is unknown whether there a subtype-specific pattern in white blood cell (WBC) WBC differential (WBCD) count.A retrospective monocentric cohort study was carried out patients with overt endogenous Cushing's syndrome (CS) or adrenal incidentalomas autonomous cortisol secretion (ACS), WBC/WBCD analysis at initial diagnosis after biochemical remission. Cut-offs were obtained by...
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides unique therapeutic option patients ineligible CAR-T and bispecific antibody therapy, and/or progressing on anti-CD38 where bispecifics might be kept in reserve. Wider use drug can challenged by its distinct ocular side effect profile, including corneal microcysts keratopathy. While dose reduction has been most effective...
This study aimed to explore the correlation between imaging patterns and clinical features in patients with smoldering multiple myeloma (SMM) who simultaneously underwent 18F-FDG, 11C-Methionine, 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT). We retrieved analyzed characteristics PET data of 10 SMM. found a significant bone marrow (BM) plasma cell (PC) infiltration mean standardized uptake values (SUVmean) lumbar vertebrae L2-L4 on 11C-Methionine PET/CT scans (r =...
Abstract The multi‐agent therapy “VDT‐PACE” represents an established regimen in relapsed/refractory multiple myeloma (RRMM). Here, we report on our experience with a “modified VDT‐PACE” incorporating new generation anti‐MM agents daratumumab and carfilzomib (“Dara‐KDT‐P(A)CE”). We retrospectively analyzed 38 patients RRMM treated “Dara‐KDT‐P(A)CE”. median age was 62 (range 45–82) years, the were heavily pretreated of 5 2–12) prior lines therapy. Twenty‐one (55%) suffered from...
Abstract Measurement of minimal residual disease (MRD) by next‐generation flow cytometry (NGF) is an important tool to define deep responses in multiple myeloma (MM). However, little known about the value combining NGF with functional imaging and its role for MRD‐based consolidation strategies clinical routine. In present study, we report our experience investigating these issues 102 patients newly diagnosed ( n = 57) relapsed/refractory MM 45). Imaging was performed using either positron...